Related Experiment Video
Updated: May 28, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Belzutifan for the treatment of renal cell carcinoma
Xiancheng Wu1,2, David Lazris3, Risa Wong4,5
1Department of Medicine, Division of Hematology and Oncology, University of Washington/Fred Hutchinson Cancer Center, 1100 Fairview Avenue N - M1-B208, Seattle, WA 98109-1024, USA.
Abstract:
Belzutifan received its first FDA approval in 2021 for treating clinical manifestations of von Hippel-Lindau (VHL) disease including renal cell carcinoma (RCC) followed by approval in 2023 for treating advanced sporadic RCC that has progressed through multiple lines of treatment. It is the first FDA-approved drug to target hypoxia-inducible factor 2 alpha (HIF-2α). By inhibiting the HIF-2α transcription factor, belzutifan prevents HIF-2α from dimerizing with HIF-1β, thereby preventing the transcription of downstream oncogenes. Most clear cell renal cell carcinoma (ccRCC) tumors are associated with VHL deletion or inactivation resulting in HIF-2α overexpression that represents a key contributor to tumorigenesis, thereby making belzutifan a uniquely optimal drug for targeting ccRCC. Belzutifan has demonstrated activity in clinical trials as a front- and later-line therapy, and in combination with tyrosine kinase inhibitors. It has been largely well tolerated, although anemia represents a common on-target side effect and, along with hypoxia, requires monitoring during treatment. Ongoing phase III trials are investigating belzutifan in combination regimens in the relapsed/refractory, front-line, and adjuvant settings. Future studies will focus on identifying predictive biomarkers and resistance pathways.
Insights
Belzutifan, the first drug targeting hypoxia-inducible factor 2 alpha (HIF-2α), effectively treats von Hippel-Lindau (VHL) disease and advanced renal cell carcinoma (RCC). Clinical trials show its efficacy as a front-line and combination therapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Von Hippel-Lindau (VHL) disease and sporadic clear cell renal cell carcinoma (ccRCC) are often driven by hypoxia-inducible factor 2 alpha (HIF-2α) overexpression due to VHL gene alterations.
- HIF-2α plays a critical role in the tumorigenesis of ccRCC, making it a key therapeutic target.
Purpose of the Study:
- To review the development and clinical application of belzutifan, a novel HIF-2α inhibitor.
- To discuss belzutifan's efficacy, safety profile, and ongoing investigations in renal cell carcinoma treatment.
Main Methods:
- Review of FDA approvals and clinical trial data for belzutifan.
- Analysis of belzutifan's mechanism of action, targeting HIF-2α.
- Examination of safety data, including common side effects like anemia.
Main Results:
- Belzutifan is the first FDA-approved drug targeting HIF-2α, initially for VHL-associated RCC and later for advanced sporadic RCC.
- Clinical trials demonstrate belzutifan's activity as monotherapy and in combination regimens.
- Anemia is a common on-target side effect requiring monitoring.
Conclusions:
- Belzutifan represents a significant advancement in ccRCC treatment by targeting the HIF-2α pathway.
- Ongoing trials are exploring belzutifan in various settings and combinations to optimize its use.
- Future research will focus on predictive biomarkers and resistance mechanisms to further refine therapy.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...